Budget impact of Saroglitazar
1 evidence topic · 1 source
Summary
The report contains an illustrative managed-access model for the Spanish National Health System, available as a preprint abstract. It assumes a net price of €25,000 per year and reports modeled net health-system costs of €4,371,005 over 24 months, with €586,495 in savings relative to its modeled price without risk sharing. These are model assumptions and outputs, not an announced commercial price or a U.S. budget-impact estimate.